We are pleased to announce 52North – creators of Neutrocheck® as new BIVDA members!
52North is a medical technology company on a mission to make urgent care pathways safer and more effective. Awarded breakthrough status for its first product Neutrocheck® by the UK Government in 2024, 52North builds in vitro diagnostic and digital solutions to transform patient journeys in urgent care.
Based in Cambridge, 52North is backed by leading UK and US hospital venture funds and other partners, including the University of Cambridge and Macmillan Cancer Support.
You can find out more about them here.
